Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose 3rd-gen EGFR-TKI +/- Intrathecal Pemetrexed for NSCLC Leptomeningeal Metastasis
NCT06441045Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in leptomeningeal metastasis (LM), sponsored by Fujian Medical University Cancer Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06441045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441045.